VASCULAR VISION PHARMACEUTICAL CO

Wynantskill, NY · Biotech · Private

Sulfated oxidized non-anticoagulant low molecular weight heparin (S-NACH) nanoformulation for sickle cell disease

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
Wynantskill, NY
Total capital
$2.8M
Federal grants
$2.5M
3 awards · 2019–2022
Rank in peer group#418 of 514
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$289K
1 award · Health and Human S
Rank in Biotech#275 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20182019202020212022FEDERAL ↑EQUITY ↓Cumulative $2.5M$289K$215K$2M
20182019202020212022FEDERAL ↑EQUITY ↓Cumulative $2.5M$289K$215K$2M

Latest events

  • Federal grantHealth and Human S · Phase II · Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$2M
  • Federal grantHealth and Human S · Phase I · Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management$215K
  • Federal contractHealth and Human S · Igf::ot::igf Topic 374: Topical Delivery Of Nanoformulated Bioactive Chemopreventive Agent In Skin Cancer$289K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • TREVIGEN, INC.Similar federal contract value in Biotech · $299K in contracts
  • GLYCOHUB, INC.Similar federal contract value in Biotech · $298K in contracts
  • CASTERBRIDGE PHARMACEUTICALS INCSimilar federal contract value in Biotech · $297K in contracts
  • Organovo, Inc.Similar federal contract value in Biotech · $284K in contracts
  • SYMBERIX, INC.Similar federal contract value in Biotech · $269K in contracts
  • ZymergenSimilar federal contract value in Biotech · $267K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .